Publications

Found 388 results
2017
Kasturi SPai, Kozlowski PA, Nakaya HI, Bürger MC, Russo P, Pham M, Kovalenkov Y, Silveira ELV, Havenar-Daughton C, Burton SL et al..  2017.  Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.. J Virol. 91(4)
Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY et al..  2017.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.. Nat Med.
Lee J H, Andrabi R, Su C-Y, Yasmeen A, Julien J-P, Kong L, Wu NC, McBride R, Sok D, Pauthner M et al..  2017.  A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.. Immunity. 46(4):690-702.
Richard J, Prévost J, von Bredow B, Ding S, Brassard N, Medjahed H, Coutu M, Melillo B, Bibollet-Ruche F, Hahn BH et al..  2017.  BST-2 Expression Modulates Small CD4 Mimetic Sensitization of HIV-1-infected cells to ADCC.. J Virol.
Martin-Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb KE, Wiesch JSchulze Zu, Cubas R, Porichis F, Shalek AK et al..  2017.  Circulating CXCR5(+)CXCR3(+)PD-1(lo) Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth.. JCI Insight. 2(2):e89574.
Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al..  2017.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373)
Antunes Rda Silva, Paul S, Sidney J, Weiskopf D, Dan JM, Phillips E, Mallal S, Crotty S, Sette A, Arlehamn CSLindesta.  2017.  Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses.. PLoS One. 12(1):e0169086.
Haynes BF, Burton DR.  2017.  Developing an HIV vaccine.. Science. 355(6330):1129-1130.
Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ et al..  2017.  Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.. MBio. 8(1)
Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M et al..  2017.  Early antibody therapy can induce long-lasting immunity to SHIV.. Nature.
Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA et al..  2017.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.. Immunity. 46(6):1073-1088.e6.
Struwe WB, Stuckmann A, Behrens A-J, Pagel K, Crispin M.  2017.  Global N-Glycan Site Occupancy of HIV-1 gp120 by Metabolic Engineering and High-Resolution Intact Mass Spectrometry.. ACS Chem Biol. 12(2):357-361.
Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park S-KRobin, Sok D, Su CYao, Delahunty CM, Menis S et al..  2017.  Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.. Nat Commun. 8:14954.
Guenaga J, Garces F, de Val N, Stanfield RL, Dubrovskaya V, Higgins B, Carrette B, Ward AB, Wilson IA, Wyatt RT.  2017.  Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein.. Immunity. 46(5):792-803.e3.
Laher F, Ranasinghe S, Porichis F, Mewalal N, Pretorius K, Ismail N, Buus S, Stryhn A, Carrington M, Walker BD et al..  2017.  HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer(+) Gag-Specific CD4(+) T Cells in Chronic Clade C HIV-1 Infection.. J Virol. 91(7)
Ward AB, Wilson IA.  2017.  The HIV-1 envelope glycoprotein structure: nailing down a moving target.. Immunol Rev. 275(1):21-32.
McCoy LE, Burton DR.  2017.  Identification and specificity of broadly neutralizing antibodies against HIV.. Immunol Rev. 275(1):11-20.
Prévost J, Zoubchenok D, Richard J, Veillette M, Pacheco B, Coutu M, Brassard N, Parsons MS, Ruxrungtham K, Bunupuradah T et al..  2017.  Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.. J Virol. 91(7)
Irimia A, Serra AM, Sarkar A, Jacak R, Kalyuzhniy O, Sok D, Saye-Francisco KL, Schiffner T, Tingle R, Kubitz M et al..  2017.  Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.. PLoS Pathog. 13(2):e1006212.
Behrens A-J, Harvey DJ, Milne E, Cupo A, Kumar A, Zitzmann N, Struwe WB, Moore JP, Crispin M.  2017.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.. J Virol. 91(2)
Ozorowski G, Pallesen J, de Val N, Lyumkis D, Cottrell CA, Torres JL, Copps J, Stanfield RL, Cupo A, Pugach P et al..  2017.  Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike.. Nature.
Escolano A, Dosenovic P, Nussenzweig MC.  2017.  Progress toward active or passive HIV-1 vaccination.. J Exp Med. 214(1):3-16.
Barouch DH, Thomas SJ, Michael NL.  2017.  Prospects for a Zika Virus Vaccine.. Immunity. 46(2):176-182.
Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, Schaefer-Babajew D, Avila-Rios S, Nogueira L, Patel R et al..  2017.  Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.. Cell. 169(4):597-609.e11.
Behrens A-J, Crispin M.  2017.  Structural principles controlling HIV envelope glycosylation.. Curr Opin Struct Biol. 44:125-133.

Pages